<DOC>
	<DOCNO>NCT00349141</DOCNO>
	<brief_summary>The objective study assess safety immunogenicity 4 different dos adjuvanted non-adjuvanted mock-up pandemic influenza vaccine . Subjects enrol sequentially 3 study cohort 4 escalate dos H5N1 hemagglutininin antigen ( 3.75 µg adjuvanted , 7.5 µg adjuvanted/non-adjuvanted , 15 µg adjuvanted/non-adjuvanted , 30 µg adjuvanted ) . Starting low dose level , subject receive 2 vaccination ( 21 day apart ) dose assign . Subjects monitor safety antibody response vaccine . A data safety monitor board review evaluate safety data obtain dose level allow administration next ( high ) dose .</brief_summary>
	<brief_title>Safety Immunogenicity Study Inactivated H5N1 Influenza Vaccine ( Whole Virion , Vero Cell Derived )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male femal subject 18 45 year age , inclusive , day screening ; understand study , agree provision , give write informed consent prior study entry ; clinically healthy , determined medical history physical examination ; agree keep daily record symptom ; female capable bearing child , negative urine pregnancy test result study entry agree employ adequate birth control measure duration study . Subjects high risk contract H5N1 influenza infection ( e.g . poultry worker ) ; suffer significant neurological , cardiac , pulmonary ( include asthma ) , hepatic , rheumatic , autoimmune , hematological renal disorder ; unable lead independent life result either physical mental handicap ; suffer kind immunodeficiency ; suffer disease undergoing form treatment expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800µg/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug ; history inflammatory degenerative neurological disease ( e.g . Guillain Barré ) ; history severe allergic reaction anaphylaxis ; rash , dermatologic condition tattoo may interfere injection site reaction rating ; receive blood transfusion immunoglobulin within 90 day study entry ; donate blood plasma within 30 day study entry ; receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study ; undergone systemic corticoid therapy within 30 day prior study entry ; functional surgical asplenia ; know suspect problem alcohol drug abuse ; administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product ; member team conduct study dependent relationship study investigator . Dependent relationship include close relative ( i.e. , child , partner/spouse , sibling , parent ) well employee investigator ; female , pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Pandemic influenza</keyword>
</DOC>